| Caitlin Miller Moore, | |
|
2235 Peacock Ln, Mountain Brk, AL 35223-1709 | |
| (269) 207-7154 | |
| Not Available |
| Full Name | Caitlin Miller Moore |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist |
| Location | 2235 Peacock Ln, Mountain Brk, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174271332 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | 1-135915 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Caitlin Miller Moore, 2235 Peacock Ln, Mountain Brk, AL 35223-1709 Ph: () - | Caitlin Miller Moore, 2235 Peacock Ln, Mountain Brk, AL 35223-1709 Ph: (269) 207-7154 |
News Archive
Previous studies have shown that proliferation of endogenous neural precursor cells cannot alone compensate for the damage to neurons and axons. From the perspective of neural plasticity, Dr. Yun Xiang and co-workers from Sun Yat-sen University in China observed the effects of functional electrical stimulation treatment on endogenous neural precursor cell proliferation and expression of basic fibroblast growth factor and epidermal growth factor in the rat brain on the infarct side.
A new monoclonal antibody therapy shows promise in offering an alternative treatment for patients suffering from moderate-to-severe asthma. Research led by Michael E. Wechsler, MD, MMSc, director of the National Jewish Health Cohen Family Asthma Institute, found that itepekimab was safe and effective in a phase 2 trial published online today in the New England Journal of Medicine.
The World NET Community announces the first Worldwide NET Cancer Awareness Day on November 10, 2010 to raise awareness about cancers called neuroendocrine tumors (NETs) and the need for timely detection and diagnosis. More than 90% of all NET patients are incorrectly diagnosed and initially treated for the wrong disease. Misdiagnoses or delayed diagnoses mean that NET patients are treated on average five to seven years for the wrong disease; often the correct diagnosis is not made until the disease has spread (metastasized).
Researchers at the Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute have concluded that short-term topical bevacizumab therapy reduces the severity of corneal neovascularization (formation of new blood vessels in the cornea that can create impaired vision or vision loss) without local or systemic adverse effects.
› Verified 2 days ago